Drug Profile
A 7183
Latest Information Update: 02 Feb 2001
Price :
$50
*
At a glance
- Originator Drug Innovation and Design
- Class Antivirals
- Mechanism of Action RNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Herpes simplex virus infections
Most Recent Events
- 02 Feb 2001 Profile reviewed but no significant changes made
- 31 Jul 1998 No-Development-Reported for Herpes simplex virus infections in USA (Topical)
- 14 Nov 1996 New profile